Initially described in 1961, Telogen Effluvium (TE) and its variants are still unclear with respect to classification, diagnosis and treatment. A new phase of the hair cycle was described by Stenn in 2002, when recognizing a proteolytic phase at the end of telogen, when shaft release occurs: the “exogen” phase.
1 Hypoxia was recognized-among other several well-documented factors, such as cytokines, hormones and nutrients-as impacting the follicle’s reentry into a new hair cycle, which was termed by Rathman-Josserand
et al. as the “neogen” phase.
2 In further development, a 2010 study by Gilmore and Sinclair suggested that chronic (TE) may be secondary to a reduction in anagen-phase variance, which would represent a new functional type of recurrent hair loss.
3